| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8222826 | International Journal of Radiation Oncology*Biology*Physics | 2013 | 6 Pages |
Abstract
The addition of gefitinib to RT is well tolerated. Median survival of RTOG 0211 patients treated with RT with concurrent and adjuvant gefitinib was similar to that in a historical control cohort treated with radiation alone.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Arnab MD, Meihua PhD, H. Ian MD, PhD, Tim MD, Walter J. MD, FACR, David G. MD, Christopher J. MD, Ali MD, Marisa MD, Jason MD, Mark MD, Annette MA, PhD, Paul MD, Adam P. MD, PhD, Markus MD, PhD, Minesh MD,